ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually providing an update on the use of its “at-the market” equity offering plan.
As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to implement an “at-the market” equity offering system under which Acasti may well issue and promote from time to time its everyday shares having an aggregate offering price of up to $75 million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares had been sold at prevailing market prices averaging US$1.0747 per share. No securities had been offered throughout the facilities of the TSXV or, to the understanding of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July seven, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with their services. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and often will supply the Company with supplemental freedom in its ongoing review process to check out and evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, development and commercialization of prescribed drugs making use of OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical evidence of safety and efficacy in lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for people with severe HTG.
Forward Looking Statements – ACST Stock
Statements in this press release that aren’t statements of historical or current truth constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking claims involve known and unknown risks, uncertainties, and other unknown factors that might cause the actual outcomes of Acasti to be materially different from historical results and even as a result of any later outcomes expressed or perhaps implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks as well as uncertainties, people are urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward looking statements, which speak simply as of the day of this particular press release. Forward-looking statements in this press release include, but are not confined to, info or statements about Acasti’s strategy, future operations as well as the review of its of strategic alternatives.
The forward-looking claims found in this press release are expressly qualified in the entirety of theirs by this alerting statement, the “Special Note Regarding Forward-Looking Statements” area found in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and on the investor area of Acasti’s site at www.acastipharma.com. All forward looking statements in this press release exist as of the particular date of this press release.
ACST Stock – Acasti doesn’t undertake to update any such forward looking statements whether as a direct result of info which is brand new, future events or even otherwise, except as called for by law. The forward looking claims contained herein are also subject generally to risks and assumptions as well as uncertainties that are described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, like Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is giving an update on the usage